Navigation Links
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
Date:7/22/2009

al, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will not receive some or all of the future milestone payments or royalties, the risk that the program does not have significant upside potential and the risk that sales of anti-VEGF antibodies do not achieve the levels projected by some market analysts. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release

    Contacts:

    Peregrine Pharmaceuticals Inc
    Investors                          
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.; Affitech A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), a ... of novel drugs in the,therapeutic areas of infection, ... for the third quarter ended September 30,2007. ... for the three months ended September 30, 2007 ...
... MS, EDMONTON, Nov. 14 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2007. "During the quarter, we continued to ... MBP8298, for the treatment of multiple,sclerosis," said Kevin ...
... Micromet, Inc.,(Nasdaq: MITI ) ("Micromet" or ... for the treatment of cancer,inflammation and autoimmune diseases, ... Company appointed Joseph P. Slattery as a member ... committee. The appointment will be,effective as of November ...
Cached Biology Technology:Advanced Life Sciences Announces Third Quarter 2007 Financial Results 2Advanced Life Sciences Announces Third Quarter 2007 Financial Results 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 4Advanced Life Sciences Announces Third Quarter 2007 Financial Results 5Advanced Life Sciences Announces Third Quarter 2007 Financial Results 6Advanced Life Sciences Announces Third Quarter 2007 Financial Results 7Advanced Life Sciences Announces Third Quarter 2007 Financial Results 8Advanced Life Sciences Announces Third Quarter 2007 Financial Results 9BioMS Medical announces third quarter 2007 results 2BioMS Medical announces third quarter 2007 results 3BioMS Medical announces third quarter 2007 results 4Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 2Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 3Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 4
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of serum long-chain omega-3 fatty acids may help reduce the ... Eastern Finland study published recently in Diabetes Care . ... oils. Type 2 diabetes is becoming increasingly widespread throughout ... factor, which means that diet and other lifestyle factors play ...
... launches today, investigating the social and political drivers and ... carbon dioxide emitter by volume, rather than focusing on ... worldwide we need to transform the way we power ... And nowhere is the approach to innovation across these ...
... been awarded to Cynthia Graber for her feature ,Electric ... regeneration?, published at MATTER. In ... journalist based in Massachusetts, investigates the work of Professor ... and Developmental Biology, to improve our understanding of the ...
Cached Biology News:Fish derived serum omega-3 fatty acids help reduce the risk of type 2 diabetes 2Story of human regeneration wins international physics journalism prize 2
... harvesting of cells • Blade design minimizes ... the growth surface • Designed for use ... wrapped • Sterilized by gamma radiation and ... a new product number, created to easily ...
... The MagneGST™ Protein Purification System ... method for the purification of glutathione-S-transferase ... particles (MagneGST™ Particles) are used to ... crude or cleared lysate using either ...
... versatile system that simultaneously harvests and washes ... into a solid filter supports for analysis ... counter. The FilterMate is ideal for the ... cell proliferation, receptor binding, nucleic acid degradation, ...
... A ready-to-use kit for a single fragment based screening project: ... each) , 96 shape-diverse mixtures of ... and dictionary files for structure refinement , ... of 4 are at ca. 50 mM. Supplied in 5 ...
Biology Products: